Viropil tablet

How does this product Work

Viropil tablet is a fixed-dose triple combination made by Emcure Pharmaceuticals Limited. Each tablet contains Dolutegravir 50 mg, Lamivudine 300 mg, and Tenofovir disoproxil fumarate 300 mg. All three active ingredients come in a single tablet. This makes supply management simpler for buyers stocking antiretroviral therapy products.

Emcure Pharmaceuticals Limited is a well-established Indian pharmaceutical manufacturer. They have a broad presence in both regulated and semi-regulated export markets.

Three distinct blocking mechanisms work together in this triple-combination tablet. Dolutegravir blocks an enzyme called integrase. The virus depends on integrase to insert its genetic material into the DNA of human immune cells. Without that step, it cannot replicate inside the host cell.

Lamivudine and Tenofovir disoproxil fumarate both belong to the nucleotide reverse transcriptase inhibitor drug class. Each one blocks the reverse transcriptase enzyme the virus uses to copy its genetic material. Together they hit the virus at two separate points in its replication cycle.

Replication slows. The viral load in the body drops measurably.

What This Product Treats

Viropil tablet is used for the management of human immunodeficiency virus type 1 infection in adults. The three-compound combination suppresses viral replication on an ongoing basis. This supports the function of the immune system over time.

It is a first-line antiretroviral regimen product. Buyers supplying clinics, pharmacies, and health program distributors stock this category regularly.

Available Strengths and Pack Sizes

The fixed-dose strength in each Viropil tablet is:

• Dolutegravir 50 mg + Lamivudine 300 mg + Tenofovir disoproxil fumarate 300 mg

This is a single-strength product. There is no lower or higher dose variant in this combination.

Pack sizes for bulk and wholesale supply should be confirmed directly through Get HIV Treatment at the time of ordering. Strip counts and carton configurations vary by shipment volume. Buyers placing a bulk order should ask about current pack availability alongside pricing.

Side Effect Profile

The side effect profile is typical of the integrase inhibitor and nucleotide reverse transcriptase inhibitor drug classes combined. Known side effects associated with these compounds include headache, fatigue, nausea, dizziness, and sleep disturbances.

Tenofovir disoproxil fumarate carries a known association with kidney function changes. Reduction in bone mineral density is also seen with long-term use. Dolutegravir has been associated with weight changes and, in some cases, elevated liver enzyme readings.

The profile is well-documented across regulatory filings from multiple countries.

Shelf Life and Storage

Store Viropil tablet below 30 degrees Celsius in a dry place away from direct light and moisture. Standard blister strip packaging protects individual tablets from humidity during transit and storage.

Buyers stocking this product in warm-climate regions should factor temperature control into warehouse planning. Shelf life details are printed on each carton and strip. Confirm expiry windows with the supplier at the time of ordering. This is especially relevant for buyers placing large wholesale orders intended for multi-month distribution.

Pricing and Availability

Get HIV Treatment carries Viropil tablet for buyers ordering at the wholesale and reseller level. Pricing is structured to support bulk purchase. Per-strip cost reduces with volume.

Contact the platform directly for current price per strip and carton pricing. Stock is regularly replenished and available for international shipment to markets where antiretroviral medicines are sourced through online pharmaceutical suppliers.

Why Buyers Stock This Product

Emcure Pharmaceuticals Limited has a strong track record in antiretroviral manufacturing for both domestic and export supply. Quality is consistent across batches. This makes Viropil tablet a reliable choice for resellers who need predictable stock for ongoing distribution contracts.

Demand for fixed-dose triple combinations in human immunodeficiency virus treatment is stable. Buyers reorder consistently. The single-tablet format reduces packaging complexity for distributors and makes this a practical product to carry.